In addition, because ER activation has been suggested to result in the reduction of sensitivity to newly-developed immunotherapy with inhibitors of programmed cell death-1 (PD-1) or its ligand (PD-L1) in, for instance, breast cancer (85), it would be interesting to assess if this can be observed in urothelial cancer. Here, PDCD1 is linked to breast carcinoma.